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Leptin Resistance
A Possible Interface of Inflammation
and Metabolism in Obesity-Related Cardiovascular Disease
Seth S. Martin, BS, Atif Qasim, MD, Muredach P. Reilly, MB
Philadelphia, Pennsylvania
Leptin is an adipocyte-derived hormone and cytokine that regulates energy balance through a wide range of
functions, including several that are important to cardiovascular health. Increased circulating leptin, a marker of
leptin resistance, is common in obesity and independently associated with insulin resistance and cardiovascular
disease (CVD) in humans. The mechanisms of leptin resistance include genetic mutation, leptin self-regulation,
limited tissue access, and cellular or circulating molecular regulation. Evidence suggests that central leptin resis-
tance causes obesity and that obesity-induced leptin resistance injures numerous peripheral tissues, including
liver, pancreas, platelets, vasculature, and myocardium. This metabolic- and inflammatory-mediated injury may
result from either resistance to leptin’s action in selective tissues, or excess leptin action from adiposity-
associated hyperleptinemia. In this sense, the term “leptin resistance” encompasses a complex pathophysiologi-
cal phenomenon. The leptin axis has functional interactions with elements of metabolism, such as insulin, and in-
flammation, including mediators of innate immunity, such as interleukin-6. Leptin is even purported to physically
interact with C-reactive protein, resulting in leptin resistance, which is particularly intriguing, given C-reactive protein’s
well-studied relationship to cardiovascular disease. Given that plasma levels of leptin and inflammatory markers are
correlated and also predict cardiovascular risk, it is conceivable that part of this risk may be mediated through leptin
resistance-related insulin resistance, chronic inflammation, type II diabetes, hypertension, atherothrombosis, and
myocardial injury. Leptin resistance and its interactions with metabolic and inflammatory factors, therefore, represent
potential novel diagnostic and therapeutic targets in obesity-related cardiovascular disease. (J Am Coll Cardiol
2008;52:1201–10) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.060a
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since its discovery more than a decade ago, leptin has been
stablished as a key regulator of energy balance (1,2).
ncreased circulating leptin, a marker of leptin resistance, is
ommon in obesity and independently associated with
nsulin resistance (3) and cardiovascular disease (CVD)
4–7) in humans. These associations may reflect the marked
etabolic dysregulation that occurs in leptin resistance as
he result of leptin’s key homeostatic physiological func-
ions. Inflammation compounds these metabolic distur-
ances because leptin regulates components of innate and
daptive immunity, including T lymphocytes and mono-
ytes (8). Leptin also has structural and functional resem-
lance to proinflammatory cytokines, such as interleukin
IL)-6 (8) and may modulate C-reactive protein (CRP) (9).
herefore, it is conceivable that the convergence of in-
reased levels of leptin and inflammatory markers (10) in
VD has a functional basis rather than mere association.
he intent of this review is to integrate knowledge on
eptin, leptin resistance, metabolism, and inflammation to
rovide a cohesive clinical perspective regarding their inter-
rom the Cardiovascular Institute, Department of Medicine, University of Pennsyl-m
ania School of Medicine, Philadelphia, Pennsylvania.
Manuscript received May 12, 2008, accepted May 28, 2008.ctions in obesity-related CVD. To this end, we discuss
undamentals of leptin, the concept and mechanisms of
eptin resistance, as well as potential pathways from leptin
esistance to CVD.
undamentals of Leptin
b/ob Mice and the Discovery of Leptin
n 1950, Ingalls et al. (11) described a new mutant strain of
bese mice (ob/ob) that were characterized by severe obesity
rom increased energy intake (hyperphagia) and decreased
nergy expenditure (reduced metabolic rate, thermogenesis,
nd physical activity). In 1973, Coleman (12) reported
eight normalization in ob/ob mice when their circulation
as connected to wild-type mice, suggesting ob/ob mice
ere deficient in a circulating factor involved in energy
alance. By using positional cloning 2 decades later, Zhang
t al. (13) at Rockefeller University isolated the ob gene
oding for this circulating factor. Shortly thereafter, recom-
inant ob gene product was administered to ob/ob mice,
orrecting their obesity (14). The ob gene product was
ubsequently named leptin, after the Greek word leptos,
eaning “thin.” Leptin’s discovery stimulated considerable
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Leptin Resistance in CVD October 7, 2008:1201–10research into the hormone’s biol-
ogy, physiometabolic function,
and impact in human disease.
Leptin: A Pleiotropic
Hormone and Cytokine
Leptin is primarily expressed in
adipocytes, and numerous hu-
man and animal studies (15–18)
have shown that leptin levels in-
crease with adiposity, presumably
to inform the brain regarding the
quantity of stored fat. Leptin also
has a structural and functional
relation to proinflammatory cy-
tokines, such as IL-6 (19), rein-
forcing its classification as an
adipocytokine” (20). These observations, coupled with the
ide expression of leptin and/or its receptor in peripheral
issues, including monocytes and lymphocytes, vascular
issue, pancreas, skeletal muscle, and myocardium (21),
uggest that leptin is pleiotropic in action and a pivotal link
n obesity-related disease. Indeed, leptin is involved in
everal processes relevant to CVD, including insulin signal-
ng, immunity, vascular function, and arterial pressure
egulation.
eptin Receptor and Signaling
eptin signals by engaging an IL-6 type glycoprotein 130
ytokine receptor, encoded by the diabetes (db) gene
22,23). Six leptin receptor isoforms are known (Ob-Ra–f)
24), which vary in length, location, and functionality. They
hare identical extracellular ligand-binding domains (second
K-F3), but differ in their intracellular domains (24). The
ost is known about Ob-Rb (also known in humans as
b-RL; L  long), which is highly expressed in the
ypothalamus and is the only isoform that activates the
anus kinase signal transduction and translation (JAK/
TAT) system. Ob-Rb and other isoforms may signal via
itogen-activated protein kinases, phosphatidylinositol
-kinase, and nitric oxide pathways. Ob-Ra is widely
istributed in peripheral tissues, shows signaling capability,
nd is thought to transport leptin across the blood-brain
arrier (25). Some isoforms may function in leptin clearance
Ob-Rc, Rd) (24) or buffering (Ob-Re; also known as
oluble leptin receptor) (26).
eptin Resistance
oncept
n the context of obesity and disease, leptin resistance began
s the idea that the body’s biomolecular milieu decreases
verall sensitivity to leptin action such that normal or,
lassically, increased levels produce an inadequate response
relative leptin deficiency). This concept (27) is reinforced
Abbreviations
and Acronyms
BMI  body mass index
CVD  cardiovascular
disease
CRP  C-reactive protein
IL  interleukin
JAK/STAT  janus kinase
signal transduction and
translation
MI  myocardial infarction
SLIP  serum leptin-
interacting protein
SOCS3  suppressor-of
cytokine-signaling-3y the observation that most obese individuals are not leptineficient but actually have increased serum leptin concen-
rations (28). The leptin resistance theory gained further
redence when a randomized, placebo-controlled, dose-
scalation trial of recombinant leptin was disappointing in
roducing weight loss in obese adults (with 20 to 30 times
ormal physiologic concentrations of leptin necessary to
roduce significant weight reduction) (29).
It is not clear whether high endogenous leptin levels are
ppropriately high in the setting of increased adiposity and
entral resistance to leptin action. However, it is clear that
hese levels, even with the addition of large amounts of
xogenous leptin, are not signaling sufficiently to maintain a
ealthy weight. Thus, in total, these observations imply that
he majority of obese patients operate on a resistant, or flat,
eptin dose-response curve, at least for weight regulation.
his phenomenon of leptin resistance may have several
ossible underlying mechanisms (Fig. 1).
echanisms
enetic mutation. Leptin resistance can be inherited,
lbeit not commonly. According to the laws of feedback
ignaling, an ob gene mutation producing leptin that is
ecreted, but ineffective at signaling, could lead to hyper-
eptinemia and leptin resistance. Similar results could be
btained through leptin receptor mutation. In fact, diabetic
db/db) mice and Zucker fatty (fa/fa) rats have dysfunc-
ional leptin receptors, causing marked hyperleptinemia and
eptin resistance (30). Although cases are found in humans,
uch mutations are uncommon in the typical obese popula-
ion (31). Thus, Mendelian inheritance patterns in leptin or
Figure 1 Mechanisms of Leptin Resistance
CNS  central nervous system; Ob  leptin gene; Ob-R  leptin receptor
gene; PTP1B  protein tyrosine phosphatase 1B; SLIP  serum leptin-
interacting protein; SLR  soluble leptin receptor; SOCS3  suppressor-of
cytokine-signaling-3.
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October 7, 2008:1201–10 Leptin Resistance in CVDts receptor are not major players in leptin resistance in the
eneral population. However, polygenetic inheritance pat-
erns in other gene products exerting influence on the leptin
xis may still contribute significantly to generational trans-
ission of genetic predisposition to leptin resistance.
elf-regulation. Like other biological signaling pathways,
eptin appears to regulate its own receptor and signaling,
nd receptor down-regulation may promote pathological
eptin resistance (32). Reduced hypothalamic leptin receptor
xpression and leptin signaling are observed in rodent
odels of age-related (33) and diet-induced (34) obesity.
he reduction appears to be a direct byproduct of increased
entral leptin. This is supported by rodent models in which
hronically increased leptin as the result of transgene over-
xpression decreased hypothalamic leptin receptor expres-
ion and protein levels, impairing leptin signaling (35).
onsistent with these models, increasing central leptin
esensitizes its physiological responses over time (36),
endering lean rodents more prone to diet-induced obesity
37). Hence, obesity promotes hyperleptinemia, which in
urn self promotes leptin resistance and further obesity,
aking leptin resistance both a consequence and cause of
besity.
imited tissue access. Resistance to leptin’s action may
ccur via limited tissue access, such as at the blood-brain
arrier. Although debate over leptin’s exact port and route
f entry into the central nervous system continues, the
urrent thought is that leptin entry is via Ob-Ra as a
aturable, unidirectional system, located in the vascular
ndothelium and choroid plexus epithelium of the blood-
rain barrier (38,39). Saturation in this transport mecha-
ism could lead to leptin resistance. Perhaps this is why
bese hyperleptinemic mice (40) and humans (41) have a
ecreased cerebrospinal fluid to serum leptin ratio. Indeed,
eptin administration into the cerebrospinal fluid of hyper-
eptinemic obese mice results in short-term weight loss (40).
owever, in the long term, limiting leptin’s brain access
ould be protective in the sense that it could prevent high
entral leptin levels and thus receptor down-regulation and
mpaired signaling. The blood-brain barrier appears to be a
ite for leptin regulation and resistance, although such
heories demand further testing.
olecular. Cellular and circulating molecules can inhibit
eptin to cause resistance (Fig. 2).
ELLULAR. Intracellular suppressor-of cytokine-signaling-3
SOCS3) is induced by and inhibits leptin JAK/STAT
ignaling (27,42), a negative feedback mechanism that is
hared with other tyrosine kinase receptors, including cyto-
ine and insulin receptors. More recently, protein tyrosine
hosphatase 1B was found to similarly regulate leptin
ignaling in cells (43). Related molecules, such as additional
OCS family members (44), cytokine-inducible SH2 pro-
ein (45), JAK binding protein (46), and STAT-induced
TAT inhibitor-1 (47), appear to regulate intracellular tytokine signaling and are candidate components of the
ntracellular leptin negative feedback loop.
IRCULATING. Extracellular circulating factors may bind
eptin, altering its bioavailability and bioactivity. In 2006,
hen et al. (9) isolated 5 serum leptin-interacting proteins
SLIPs) in human blood by using leptin-affinity chroma-
Figure 2 Theoretical Cellular and Molecular
Mechanisms of Leptin Pathophysiology
(A) In leptin-resistant tissue (e.g., hypothalamic cell illustrated), serum leptin-
interacting proteins (SLIPs) and soluble leptin receptor (SLR) may bind circulat-
ing adipose-secreted leptin and inhibit its action. Free leptin engages the long
form of its receptor (Ob-Rb), which homodimerizes. Intracellularly, activated
janus kinase 2 (JAK2) phosphorylates a specific tyrosine docking site (Tyr1138)
on Ob-Rb. Signal transduction and translation protein 3 (STAT3) recognizes and
binds to activated Tyr1138 via its src homology 2 (SH2) domain. The Ob-Rb/
JAK2 complex activates STAT3, which homodimerizes, then translocates to the
nucleus to modulate gene transcription. STAT3 up-regulates expression of sup-
pressor-of cytokine-signaling-3 (SOCS3) and protein tyrosine phosphatase 1B
(PTP1B), which block JAK2 phosphorylation. It is thought that central leptin
resistance promotes obesity, driving greater hyperleptinemia. (B) In nonleptin-
resistant tissue (e.g., immune cell illustrated) exposed to hyperleptinemia,
Ob-Rb may signal excessively through multiple signaling pathways, including
JAK/STAT, insulin receptor substrate-2/phosphatidylinositol 3-kinase (IRS-2/
PI3K), and nitric oxide that may ultimately promote cardiovascular disease
(CVD) through tissue-specific mechanisms.ography, mass spectrometry, and immunochemical analy-
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Leptin Resistance in CVD October 7, 2008:1201–10is. The group identified SLIP-1 as CRP (9) and SLIP-2 as
PO-J (also known as clusterin) (48), whereas SLIPs 3–5
re yet to be further characterized. The concept of circulat-
ng leptin binding proteins is not new. In fact, Ob-Re, the
oluble leptin receptor, is known to bind leptin in the
irculation (49), reducing its free concentration and activity
50). Recently described SLIPs were distinct from and
resent in significantly greater concentrations than soluble
eptin receptor.
The report by Chen et al. (9) frames a role for human
RP in the induction of leptin resistance via direct physical
nteraction. In vitro investigation demonstrated the ability
f human CRP to directly inhibit leptin binding to its
eceptor and related cell signaling in HEK293 cells or
ypothalamic neurons in contrast to IL-6, which also
ppears to bind to CRP, but without a change in cell
ignaling (51). In ob/ob mice, increased human CRP from
ontinuous infusion or transgene expression attenuated the
hysiological actions of exogenous leptin on food intake,
ody weight, blood glucose, and lipid metabolism (9).
oreover, physiologic leptin concentrations boosted CRP
xpression in vitro in human primary hepatocytes. Corre-
pondingly, studies in healthy humans show a strongly
ositive independent association between leptin and CRP
lood concentrations (52,53). Clinical investigations of
hether leptin administration in vivo enhances CRP con-
entration were positive in nonobese individuals (54,55) but
egative in obese subjects (56), perhaps attributable to leptin
esistance. Therefore, preliminary evidence points to an
dipohepato axis, whereby leptin enhances CRP expression
nd CRP, in turn, may antagonize leptin action. These
ndings are provocative for a functional CRP effect, as well
s for an interface of metabolism and inflammation in the
athogenesis of cardiometabolic disease.
However, the role of CRP in the induction of leptin
esistance and as a mediator in CVD is not yet established.
imiting acceptance is the absence of an explicit mechanism
y which CRP causes leptin resistance. For instance, re-
arding leptin’s central action, it is not known whether CRP
nhibits leptin inside or outside the central nervous system.
urthermore, Chen et al’s (9) proposed leptin-CRP inter-
ction prompted a robust correspondence and data against
uch an interaction (57–59). A reply from Zhao (48), a
ember of Chen’s group, offered explanations for the
pparent discrepancies. This debate emphasizes the need for
alidation of the leptin-CRP interaction in humans and the
se of careful experimental technique in this pursuit, par-
icularly as species specificity limits the utility of rodent
odels (60).
athways From Leptin Resistance to CVD
nnate Immunity, Inflammation, and Atherosclerosis
eptin may be directly atherogenic (61). Ob/ob mice are
esistant to atherosclerosis (62), and leptin receptors have
een detected in human atherosclerotic lesions (63). Con- hidering that atherosclerosis is increasingly viewed as an
nflammatory disease, driven by lipoproteins, metabolic
ignals, hemodynamic stress, and the integrated activity of
mmune cells and inflammatory cytokines, it is intriguing
hat leptin and inflammatory pathways demonstrate recip-
ocal modulation and shared association with cardiovascular
isk. Leptin regulates human immune functions (64),
hereas activation of innate immunity induces leptin in
odents (65) and humans (66–68). T-cell hyporesponsive-
ess is a core manifestation of leptin deficiency in mice (69)
nd humans (64). In fact, several immune cells implicated in
therosclerosis, including T lymphocytes, monocytes, and
acrophages, bear the leptin receptor and generally are
ctivated by leptin (8). Leptin stimulates central T-cell
roduction and a peripheral shift in favor of T helper (Th)
adaptive immune responses (proinflammatory) as opposed
o Th2 responses (anti-inflammatory). Further augmenting
he inflammatory milieu that fosters atherosclerosis, leptin
romotes intimal monocyte recruitment (70), elicits macro-
hage foam cell formation (71), and induces secretion of
roinflammatory (8), atherogenic cytokines. In this setting,
eptin itself can be considered to be a proinflammatory
ytokine.
Notably, multiple downstream inflammatory biomarkers,
ncluding CRP, are independent predictors of CVD (66).
espite correlations with CRP, levels of several macrophage
nd T-cell cytokines, including IL-18, IL-6, and tumor
ecrosis factor-alpha, have also been associated with coro-
ary artery calcification, incident myocardial infarction
MI), and recurrent CVD in most (72–74) but not all (75)
rospective epidemiological studies. Recent evidence sug-
ests that leptin induces CRP expression in human coronary
rtery endothelial cells (76), where CRP itself may promote
therosclerosis (77). Overall, multiple immune and inflam-
atory pathways, which may be modulated by leptin,
yperleptinemia, and leptin resistance, have been implicated
n atherosclerosis in humans as well as in experimental
odels (10).
A limited pool of data is available on the association of
eptin with measures of subclinical atherosclerosis in hu-
ans. In a study population of 200 type II diabetic patients
ithout clinical manifestations of CVD, we found an
ssociation between plasma leptin levels and coronary artery
alcification, even after controlling for established risk
actors, adiposity, and CRP (7). Recently, we also reported
positive relationship between plasma leptin and coronary
alcification in 860 nondiabetic healthy adults independent
f established CVD risk factors (78). In 126 normal-weight
r obese, but otherwise healthy patients, an association of
eptin with intima-media thickness of the common carotid
rtery was attenuated after adjustment for body mass index
BMI) (79). In addition, several small studies failed to
stablish an association between leptin and intima-media
hickness, including in obese or type I diabetic children (80),
ealthy elderly men (81), and healthy obese women (82).
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October 7, 2008:1201–10 Leptin Resistance in CVDhus, the relation of leptin to subclinical atherosclerosis in
umans requires further study.
Several clinical studies have correlated leptin levels with
ardiovascular events. The first of these reports, from
oderberg et al. (4), saw a positive association of plasma
eptin with first MI, independent of traditional risk factors,
n a small, population-based case-control study. In the
argest of these studies to date, a case-control analysis of
ore than 1,000 hypercholesterolemic patients, Wallace
t al. (5) found that plasma leptin positively predicted acute
ardiovascular events (MI, need for revascularization,
eath), after adjusting for BMI, plasma glucose, lipids, and
RP. Other investigations have connected hyperleptinemia
ith stroke (83,84) and major adverse cardiac events (6),
ncluding restenosis, after percutaneous coronary interven-
ion (85). In contrast, conflicting data come from 2 small
nalyses in which plasma leptin levels were unrelated to (86)
r negatively predicted (87) CVD. All told, most data favor
ositive cardiovascular risk prediction for both inflammatory
arkers and leptin. Thus, it is important to further dissect
he diverse mechanisms that may underlie this convergence
n CVD (Fig. 3).
nsulin resistance and diabetes. Diabetes and insulin re-
istance are major cardiovascular risk factors. It is not
urprising that leptin interacts with other hormonal regula-
ors of energy metabolism, such as insulin. Interestingly,
eptin-deficient mice (11,14) and humans (60,64,88) have
iabetic features, which correct with leptin replacement
ven before weight loss. One can infer that leptin resistance
a state of relative leptin deficiency) would lead to insulin
esistance and diabetes. This idea of leptin as an insulin-
Figure 3 Overview of Leptin Resistance and Hyperleptinemia
in Obesity-Related Cardiovascular Disease
A leptin-resistant/hyperleptinemic state is a putative link between obesity and
diverse vascular and myocardial injury via direct effects or intermediary disor-
ders. The site of effect (central vs. peripheral) is depicted.ensitizing hormone and leptin deficiency, or resistance, as a sotential link between obesity and diabetes has been re-
iewed recently (89). Indeed, leptin-induced SOCS3 results
n resistance to insulin receptor signaling. As a cautionary
ote, the bulk of literature comes from in vitro and animal
tudies and there have been some inconsistencies between
eports. However, one cannot overlook the accumulating
ody of work supporting the direct involvement of leptin in
lucose homeostasis.
Human data show that basal plasma leptin and insulin
oncentrations parallel each other (90,91). Increased
eptin is associated with hyperinsulinemia and insulin
esistance, independent of BMI (3). Consistent with a
idirectional adipoinsular axis, insulin and glucose appear
o stimulate leptin secretion in adipocytes (92–94). In-
eed, insulinoma elevates leptin levels (95). In response,
eptin decreases insulin secretion via direct action on
eptin receptors in pancreatic B-cells (96) while enhanc-
ng skeletal muscle glucose uptake and oxidation (97,98)
nd suppressing hepatic glucose production (99). Fur-
hermore, leptin might reduce lipotoxicity (triglyceride
ccumulation in nonadipose tissue which contributes to
nsulin resistance) and consequently improve hepatic,
uscular, and whole body insulin sensitivity (100).
Although leptin therapy was disappointing in trials of
ommon obesity (perhaps because of leptin resistance), it
as shown success in other patient populations. For in-
tance, leptin therapy improved diabetic measures in chil-
ren (60,64) and adults (101) with familial leptin deficiency
nd in patients with lipoatrophic diabetes (102). Taken
ogether, these data imply that leptin resistance may induce
nsulin resistance and diabetes. In view of recent evidence
hat inflammatory cell infiltration promotes adiposity, insu-
in resistance, and type II diabetes (103) and that increased
L-6 and CRP predict incident type II diabetes (104–106),
t is intriguing to consider a leptin–CRP interaction as a
ossible mechanism linking these disorders.
ypertension. Hypertension is a major cardiovascular risk
actor linked to hyperleptinemia and leptin resistance.
ross-sectional investigations in human subjects show in-
reasing leptin concentrations with increasing blood pres-
ure in subjects in both the normotensive (107) and hyper-
ensive range (108–110). Moreover, hypertensive, overweight
omen have greater levels of leptin than their normotensive
ounterparts (111). Possible causal pathways for hyperleptine-
ia in hypertension, based mainly on animal studies, were
escribed in detail in recent reviews (112–115). In brief,
hronic leptin-mediated central sympathetic activation, origi-
ating in the hypothalamus, results in a systemic pressor effect
hat is believed to play a chief role in obesity-related hyperten-
ion. In the kidney, sympathoactivation, along with de-
reased natriuresis leading to volume retention, may con-
ribute to increased blood pressure. Conversely, there is the
uggestion, but lack of consensus, that leptin decreases
rterial tone in the vascular wall through direct actions on
he endothelium and smooth muscle, although uncertainty
urrounds the mechanism of action, acute versus chronic
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Leptin Resistance in CVD October 7, 2008:1201–10ffects, and the relevance to human physiology. Regardless,
hronic infusion or transgenic overexpression of leptin
nduces hypertension pointing to a sympathetic pressor
ffect as the dominant hemodynamic action of leptin, at
east over the longer term.
The paradoxical notion of a leptin-mediated pressor effect
ersisting in the setting of an otherwise leptin-resistant state
ight be reconciled by the concept of selective leptin
esistance (Table 1) (116). It posits that certain actions of
eptin (e.g., sympathoexcitatory actions) persist despite re-
istance to others. This concept is supported by data from
urine models of genetic (117) and diet-induced obesity
118). Yet, how leptin resistance blocks some actions of
eptin, but not others, is not clearly understood, especially
utside of rodent models. A leading hypothesis is that
ost-receptor leptin signaling encounters greater feed-
ack (e.g., greater SOCS3 concentration) in resistant
issues, compared with nonresistant tissues (119). Other
ossibilities include differential leptin tissue access and
irculating leptin inhibitors. Such hypotheses call for
urther testing.
hrombosis
eptin may be prothrombotic. Ob/ob mice show impaired
hrombus formation in response to vascular injury that is
eversed by leptin replacement (120,121), suggesting leptin
ignaling promotes arterial thrombosis. One target of such
ignaling may be platelets. Ob-Rb is found on platelets
122) and leptin enhances platelet aggregation in the pres-
nce, but not in the absence, of this receptor (121).
lthough high concentrations of leptin corresponding to
evels in obese individuals increase platelet aggregation,
ower concentrations do not (122). This result suggests that
eptin’s prothrombotic effect might be limited to obese
yperleptinemic individuals, thus acting as a unique link
etween obesity and cardiovascular events. Coagulation-
brinolysis balance represents a second possible system for
eptin mediated thrombosis. Leptin levels have been posi-
ively correlated with plasminogen activator inhibitor-1
123–125), fibrinogen (126), von Willebrand factor (126),
nd factor VIIa (127) and negatively correlated with tissue
lasminogen activator (125,128), tissue factor pathway in-
heoretical Model of Selective Leptin Resistance and Hyperleptine
Table 1 Theoretical Model of Selective Leptin Resistance and
Resistant
Tissue Hypothalamus (metabolic centers)
pancreas, liver
Leptin concentration High
Pathophysiology Insensitivity to leptin (relative lepti
causes disesase
Disease manifestations Obesity, insulin resistance, diabete
Response to exogenous leptin Disease improvement
Potential of response to targeted treatment
of leptin resistance/hyperleptinemia
Disease improvementibitor (129), and protein C (129). These findings from larious human cohorts imply that increased leptin concen-
ration, either as a marker or through direct effect, favors
oagulation over fibrinolysis. The concept of leptin as
rothrombotic is of clinical importance because it could
irectly implicate leptin resistance in acute CVD beyond a
elationship with atherosclerosis. It is noteworthy, in fact,
hat leptin was an independent predictor of acute cardio-
ascular events in patients with angiographically confirmed
oronary disease (6). Overall, whether via platelets or
lotting factors, high leptin may confer risk for thrombosis.
yocardial Injury
eptin signaling may alter cardiomyocyte structure and
unction, as thoroughly reviewed recently by Yang and
arouch (130). Evidence implicates the leptin axis in
ecreased cardiomyocyte contractility and through nitric
xide, B-adrenergic intermediates, reactive oxygen species,
eramide, and proinflammatory factors. Contractility may
lso be impaired by cardiac lipotoxicity secondary to de-
reased fatty acid oxidation in late-stage leptin resistance in
ontrast to the increased fatty acid oxidation that character-
zes early leptin resistance and protects from steatosis. This
xample draws an important distinction between early- and
ate-stage leptin resistance, which may turn out to be
onceptually similar to the progression found in insulin
esistance towards type II diabetes. Besides antisteatosis, the
dditional benefits of short-term hyperleptinemia may in-
lude compensatory cardiac hypertrophy and protection
rom ischemia/reperfusion injury. Yet, chronically, leptin-
elated cardiomyocyte hypertrophy, proliferation, apoptosis,
nd extracellular matrix reorganization may all contribute to
aladaptive cardiac remodeling in obesity. Hypertrophic
nd proliferative effects may account for the observation
hat, independent of blood pressure, fasting plasma leptin
evels are positively associated with left ventricular hyper-
rophy in hypertensive patients (131).
Leptin signaling pathways in the myocyte are compli-
ated by different isoform signaling capabilities but, as
etailed (130), significant progress has been made in eluci-
ating pathological disturbances in cardiac disease, includ-
ng in the JAK/STAT, mitogen-activated protein kinase,
itric oxide, and B-adrenergic pathways. In myocardium,
n Cardiovascular Disease Pathophysiology
leptinemia in Cardiovascular Disease Pathophysiology
Nonresistant
tal muscle, Immune cells, clotting factors, platelets, vessel wall, myocardium,
sympathetic nervous system
High
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October 7, 2008:1201–10 Leptin Resistance in CVDroduce the same result, perhaps because hyperleptinemia
eflects a state of leptin resistance and, thus, functional
eptin deficiency. However, whether leptin resistance occurs
n the myocardium itself is not yet firmly established. Faced
ith these issues, we can expect continued challenge in
ttempting to isolate the physiological actions of leptin from
athological ones in leptin deficiency, resistance, or excess.
eptin Resistance and the
besity Epidemic in Evolutionary Terms
eptin resistance and the surfacing of the obesity epidemic
re logical when viewed in the context of evolution. Rapid
nvironmental changes introduced by industrialization,
amely increased food availability and decreased physical
xertion, were in sync with the increase in obesity. This
nvironmental change presumably had such an impact
ecause it exerted its influence on a human biological system
ith a propensity for obesity. Such propensity likely stems
rom an evolutionary survival advantage, in the face of
eriodic famine, injury, or infection, for those best equipped
o store energy at times of nutritional abundance.
nflammation-related induction of CRP or other leptin
nhibitors with attenuation of central leptin signaling would
romote adiposity, the most efficient energy depot in
umans. Evolutionarily pre-programmed to store energy, it
s not surprising that entry of humans into the energy-dense
odern society has resulted in the emergence of obesity as
major public health issue. It appears our biological system
egulating energy balance has taken on a maladaptive role,
hich may lead to a host of negative cardiometabolic
onsequences.
onclusions
fter a doubling in obesity during the last quarter century,
pproximately one-third of American adults have been
lassified as obese and two-thirds as overweight (132).
hese figures highlight the need to better understand the
tiology of obesity and find effective treatments. Leptin
esistance may be an interface of metabolic dysregulation
ith inflammation in the pathogenesis of obesity, its co-
orbidities, and ultimately CVD. Such an interface pro-
ides one possible pathophysiological explanation for the
onvergence of leptin and inflammatory biomarkers in
rediction of CVD in humans.
Several questions need to be addressed. For example,
armful leptin effects arising in an otherwise leptin resis-
ance state raise the question of selective leptin resistance. If
his exists, how does it occur? Are cellular and circulating
nhibitors of leptin signaling major players in leptin resis-
ance and capable of tissue-selective effects in humans? Such
uestions underscore that much is yet to be defined, but
hould help focus basic and translational research. The
otential clinical implications of leptin resistance are pro-
ocative. First, leptin resistance may represent an integrated
arker for the inextricably linked disease states of obesity,etabolic syndrome, insulin resistance, type II diabetes,
ypertension, atherothrombosis, and myocardial disease
133). More study is needed to determine whether leptin
esistance markers would be valuable in future approaches to
ardiovascular risk stratification in clinical practice. Second,
nowledge of the mechanisms of leptin resistance, particu-
arly tissue selectivity, cellular mechanisms, and circulating
odulators (e.g., SLIPs) may direct us toward therapeutic
nterventions aimed at overcoming leptin resistance. For
xample, molecules that alter the bioavailability of circulat-
ng leptin (e.g., interfere with leptin interactions with
LIPs) or modify post-receptor signaling (e.g., block
OCS3 actions) might represent new targets for therapeutic
evelopment. These therapeutic possibilities add promise in
ombating the obesity epidemic and its devastating conse-
uences. This background provides impetus for further
nvestigation of leptin resistance.
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